GlassScriptPhysician profile
Manuel Moquete
NPI 1568564102
$733.93
in general payments reported to CMS, 2019-2025
9 companies · $53.69 in 2025
The $53.69 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.93 · 2022: $239 · 2023: $15.99 · 2024: $338 · 2025: $53.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $252.37 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $136.34 | 2024 | Farxiga |
| Opko Pharmaceuticals, LLC | $123.45 | 2024 | Rayaldee |
| Medtronic, INC. | $65.99 | 2021-2023 | Chameleon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.78 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $36.93 | 2021 | |
| Amgen INC. | $36.63 | 2025 | Tavneos |
| Vifor Pharma, INC. | $17.06 | 2024 | Veltassa |
| Horizon Therapeutics Plc | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Moquete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.